| Bioactivity | CIAC001 is a Pyruvate Kinase PKM2 inhibitor with anti-neuroinflammatory activity. CIAC001 inhibits LPS-induced proinflammatory nitric oxide (NO) production and protects immunologically active BV-2 cells (IC50=2.5 μM). CIAC001 also has anti-neuroinflammation in mouse models and inhibits chronic morphine-induced addiction[1]. |
| Target | PKM2 |
| Invitro | CIAC001（10 μM；6 小时）抑制 BV-2 细胞中 LPS (200 ng/mL) 诱导的小胶质细胞形态变化[1]。 0 --> CIAC001 相关抗体: |
| In Vivo | CIAC001（20 μg/kg 和 0.2 mg/kg，腹膜内注射，每天一次，持续 7 天）剂量依赖性地减弱吗啡依赖性小鼠中 Naloxone (HY-137279, 阿片类受体拮抗剂) 诱发的戒断跳跃，并显着抑制诱导期吗啡诱导的行为敏化的发展[1].CIAC001（20 mg/kg，腹腔注射，每天一次，持续 7 天）在小鼠 Y 迷宫测试中显示它没有明显导致记忆衰退或认知障碍的能力[1] 。 |
| Name | CIAC001 |
| CAS | 2649154-82-3 |
| Formula | C20H25N3O2 |
| Molar Mass | 339.43 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Jin S, et al. Cannabidiol Analogue CIAC001 for the Treatment of Morphine-Induced Addiction by Targeting PKM2. J Med Chem. 2023 Aug 24;66(16):11498-11516. |